Buparlisib (BKM120, NVP-BKM120)

目录号：S2247

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献135篇：

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )
Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )
Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )

Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )
J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	NH71N\|hEgXSxdH;4bYMhSXO\|YYm=		MmPKO\|IhcA>?	MXTEUXNQ	NYrqbppwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=>	M1PUNVI1QTByMk[2
DU145	MlHGR5l1d3SxeHnjJGF{e2G7		NWjvd\|JLPzJiaB?=	NYe5d\|ZvTE2VTx?=	NIDxXWNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2=	MlrKNlQ6ODB{Nk[=
A2780	MXHDfZRwfG:6aXOgRZN{[Xl?		NWrac29QPzJiaB?=	NVPzZplmTE2VTx?=	NX24eJV2S3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=>	NYL5dXhbOjR7MECyOlY>
U87MG	M1yyXWN6fG:2b4jpZ{BCe3OjeR?=		M1rUd\|czKGh?	MVHEUXNQ	NX:zb\|NtS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjl6IN88US=>	MmTHNlQ6ODB{Nk[=
A2780	Mn:1SpVv[3Srb36gRZN{[Xl?		NH;3UlkyKGh?	M4nRdWROW09?	M{fFS2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh\|ryP	MXmyOFkxODJ4Nh?=
DU145	MnLISpVv[3Srb36gRZN{[Xl?		Mm\BNUBp	M2HuOWROW09?	Mkn3TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1?	MUSyOFkxODJ4Nh?=
A2780	M360[GZ2dmO2aX;uJGF{e2G7		Ml\XNUBp	MYjEUXNQ	M17SdmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	M3PNXlI1QTByMk[2
MCF7	NFHVPINHfW6ldHnvckBCe3OjeR?=		MljSNUBp	Mnr4SG1UVw>?	MYHJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0>	NHSwU3QzPDlyMEK2Oi=>
U87MG	NGG2b5lHfW6ldHnvckBCe3OjeR?=		MV2xJIg>	MWPEUXNQ	NV;vRpdPUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?=	NWO0[pBmOjR7MECyOlY>
A2780	NFj1NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVW1e4JYPzJiaB?=	MV3EUXNQ	NFjsXJVGSzVyPUCuOVIh\|ryP	M{PKOlI1QTByMk[2
SKMES-1	MYnDfZRwfG:6aXOgRZN{[Xl?	M4f5OVEh\|ryP	M{jOPVczKGh?		MorpTY5lfWOnczDj[YxtKGSnYYTo	M3GzSlI3ODF\|M{G4
H596	MlTYSpVv[3Srb36gRZN{[Xl?	NHPqZo4yKM7:TR?=			NHn3XZBKdXCjaYLzJINmdGxibXnndoF1cW:w	MnjYNlYxOTN\|MUi=
HCC2450	Mk\KSpVv[3Srb36gRZN{[Xl?	M{f5WVEh\|ryP			MXvJcZBicXK\|IHPlcIwhcW64YYPpc44>	MV:yOlAyOzNzOB?=
A549	MYHGeY5kfGmxbjDBd5NigQ>?	NWe5fG5LPTByIH7N	MoW4OFghcA>?	MXrEUXNQ	M2HISmlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w	NYTjUIhrOjV7M{eyPVk>
A549	M1rOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmxJO69VQ>?	Ml7sO\|IhcA>?	NV;abW5bTE2VTx?=	NF\iZ21KdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NIHpc3AzPTl\|N{K5PS=>
H522	NHjLRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzJbZJWOSEQvF2=	NIjv[5k4OiCq	MVLEUXNQ	Mm\zTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NV\YTXZNOjV7M{eyPVk>
LNCaP	NHHaWmVHfW6ldHnvckBCe3OjeR?=	M1zZXVEh\|ryP			M4PFNXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	NFu4PVkzPTN4MEe5PS=>
LNCaP95	NYCx[pNsTnWwY4Tpc44hSXO\|YYm=	Mn7UNUDPxE1?			NV\HPYYzW3WycILld5NmeyCyLVHLWEBt\X[nbIO=	NV7FN5A2OjV\|NkC3PVk>
HCT-15	NVXQXYRJSXCxdH;zbZMhSXO\|YYm=	MXWxNEDPxE1?	MXG0PEBp	NXK5XWozTE2VTx?=	NWLjXGZTUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVE2KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36=	NGLNS4EzPTF3MkK0OS=>
HCT-116	M4LuWmFxd3Sxc3nzJGF{e2G7	M3Pt[VExKM7:TR?=	M{P0TVQ5KGh?	NIG5dGZFVVOR	NXuzdVNEUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVEyPiClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	MlnCNlUyPTJ{NEW=
NCI-H460	NHG3[GdCeG:2b4Ppd{BCe3OjeR?=	MV[xNEDPxE1?	M{\aNFQ5KGh?	NEe3RYRFVVOR	MYfJcoR2[2W\|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NX;UfW55OjVzNUKyOFU>
SKOV-3	MWTBdI91d3OrczDBd5NigQ>?	NH;LS\|IyOCEQvF2=	M4nBPFQ5KGh?	NEHuN5JFVVOR	M2HQXmlv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NETvcJgzPTF3MkK0OS=>
BSY-1	MoTtRZBwfG:\|aYOgRZN{[Xl?	Mn7ENVAh\|ryP	Mn36OFghcA>?	NIT2TpdFVVOR	MUPJcoR2[2W\|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	MnvHNlUyPTJ{NEW=
MKN-1	Mn;YRZBwfG:\|aYOgRZN{[Xl?	NHPWSXgyOCEQvF2=	NGDMOXE1QCCq	MknZSG1UVw>?	NV\lSXV6UW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	NGTPc5YzPTF3MkK0OS=>
NCI-H522	NXnzTG5VSXCxdH;zbZMhSXO\|YYm=	M3;RT\|ExKM7:TR?=	MnnuOFghcA>?	MlXFSG1UVw>?	NH\oeXlKdmS3Y3XzJIFxd3C2b4Ppdy=>	NU\lNZRnOjVzNUKyOFU>
OVCAR-3	Ml6zRZBwfG:\|aYOgRZN{[Xl?	MV:xNEDPxE1?	MmqxOFghcA>?	NIG1fYlFVVOR	NVnUXolKUW6mdXPld{BieG:ydH;zbZM>	M37pOVI2OTV{MkS1
HBC-5	NUXTdGlZSXCxdH;zbZMhSXO\|YYm=	NULLZ3hLOTBizszN	MYW0PEBp	NULrUFBoTE2VTx?=	M4jVbWlv\HWlZYOgZZBweHSxc3nz	NVfhTG9LOjVzNUKyOFU>
RXF-631L	MmD0RZBwfG:\|aYOgRZN{[Xl?	M4TlUFExKM7:TR?=	NXu4R2w1PDhiaB?=	NEGySZhFVVOR	M{fsb2lv\HWlZYOgZZBweHSxc3nz	NHfpVZkzPTF3MkK0OS=>
MKN-45	NUXVNodESXCxdH;zbZMhSXO\|YYm=	MmfhNVAh\|ryP	NHHQNpU1QCCq	NYjkd2c{TE2VTx?=	MnTBTY5lfWOnczDhdI9xfG:\|aYO=	Mkf4NlUyPTJ{NEW=
BON-1	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\LOVAxKG6P	NUH4XpV{OTBiZB?=	NVvMcWRHTE2VTx?=	MX;Jcohq[mm2czDj[YxtKGe{b4f0bC=>	NVXRNodKOjVyMk[yPVI>
BON-1	MU\GeY5kfGmxbjDBd5NigQ>?	MlL0OVAxKG6P	NUHmNIF3PCCq	MYfEUXNQ	NYCxTnhZUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ\|MEigZY5lKFOnckS3Ny=>	NEXMOYYzPTB{NkK5Ni=>
QGP-1	M1i1OGZ2dmO2aX;uJGF{e2G7	NYfvSZhQPTByIH7N	NXXt[I5RPCCq	M33ZN2ROW09?	NWXLO\|lyUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ\|MEigZY5lKFOnckS3Ny=>	MnXkNlUxOjZ{OUK=
Huh7	NVSwbmJKTnWwY4Tpc44hSXO\|YYm=	Mnq2NUDPxE1?	NYrVVnJsOSCq	NHLQXJdFVVOR	MoXvTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR?	MYmyOVAxPDRyMx?=
BNL	MXXGeY5kfGmxbjDBd5NigQ>?	M2O5RlEh\|ryP	M3fzXFEhcA>?	MmPWSG1UVw>?	NHqz[XNKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhWzZ?	M1;VbFI2ODB2NECz
MDA-MB-175	NGizcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q1S\|Eh\|ryP	MnrZOUBl	MlrTSG1UVw>?	M3;VOWlEPTB:MTFOwG0>	Mo\JNlQ5Pzl5OU[=
MDA-MB-134	NYXRd3FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXH5WVg2OSEQvF2=	NXqxUmd5PSCm	MoDQSG1UVw>?	MmPmTWM2ODxzIN88US=>	M{XHTFI1QDd7N{m2
HCC1500	NGC3WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fHe\|Eh\|ryP	M3[0dlUh\A>?	NUnvWYVKTE2VTx?=	NUXhWGVlUUN3MEyxJO69VQ>?	MlizNlQ5Pzl5OU[=
EFM-19	M4jmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrpNUDPxE1?	MXi1JIQ>	NF\jSoJFVVOR	NVzPR4R6UUN3MEyxJO69VQ>?	Ml34NlQ5Pzl5OU[=
ZR-75-30	NWfzZmRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTSNUDPxE1?	NGmwR\|g2KGR?	MVnEUXNQ	Mly0TWM2ODxzIN88US=>	NXzuUldqOjR6N{m3PVY>
MDA-MB-361	NWG3[lRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXmNUDPxE1?	NVHLcXBDPSCm	NWDvXWlLTE2VTx?=	MYrJR\|UxRDFizszN	MVyyOFg4QTd7Nh?=
T-47D	NWrofGdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTqTZN2OSEQvF2=	M1P5cVUh\A>?	MkHwSG1UVw>?	MYTJR\|UxRDFizszN	MViyOFg4QTd7Nh?=
SK-BR-3	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O1b\|Eh\|ryP	MWC1JIQ>	NIHpflhFVVOR	Mki3TWM2ODxzIN88US=>	NXu1e3hbOjR6N{m3PVY>
UACC-732	MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojoNUDPxE1?	NHTROIo2KGR?	MYnEUXNQ	NEnxc3JKSzVyPEGg{txO	NWPvfYUyOjR6N{m3PVY>
BT-474	NH7oZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxJO69VQ>?	M33T[lUh\A>?	MVHEUXNQ	NWLzdG9YUUN3MEyxJO69VQ>?	MoXYNlQ5Pzl5OU[=
HCC202	M1\yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Kz[\|Eh\|ryP	NV:0Z4ZNPSCm	NWHYOWZtTE2VTx?=	NGDJeZZKSzVyPEGg{txO	NXW5S2NCOjR6N{m3PVY>
MCF7	NYPKVod{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLkN3EyKM7:TR?=	MkP3OUBl	NVPPWZk2TE2VTx?=	M3HKfmlEPTB:MTFOwG0>	MWSyOFg4QTd7Nh?=
MDA-MB-415	NVHlUmxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7nNUDPxE1?	NV;SU4hpPSCm	MmDESG1UVw>?	NEfQOmtKSzVyPEGg{txO	Ml\6NlQ5Pzl5OU[=
MDA-MB-453	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVSxJO69VQ>?	MmqxOUBl	MkC3SG1UVw>?	Mnm3TWM2ODxzIN88US=>	MnyxNlQ5Pzl5OU[=
ZR-75-1	M17QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP2NFY4OSEQvF2=	NVnh[4prPSCm	NXjqcpBoTE2VTx?=	NHjaWFNKSzVyPEGg{txO	M2DmSFI1QDd7N{m2
HCC38	NXzvPVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXsNUDPxE1?	NGr5XmI2KGR?	NVPKN\|FPTE2VTx?=	MofCTWM2ODxzIN88US=>	MlPDNlQ5Pzl5OU[=
HCC1419	NGHQU\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C5N\|Eh\|ryP	NYDsXXlQPSCm	MWDEUXNQ	M2PIWWlEPTB:MTFOwG0>	M4\2blI1QDd7N{m2
UACC-812	M3TZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGyXJBUOSEQvF2=	NYnNZ2lCPSCm	NFnkRmlFVVOR	M13VVWlEPTB:MTFOwG0>	Mn3rNlQ5Pzl5OU[=
HCC1187	M1jBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWro[HFSOSEQvF2=	MXy1JIQ>	MlzaSG1UVw>?	MWLJR\|UxRDFizszN	MlrONlQ5Pzl5OU[=
KPL-1	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrLW2kyKM7:TR?=	NE\UfZQ2KGR?	NWXJe296TE2VTx?=	MXzJR\|UxRDFizszN	MYmyOFg4QTd7Nh?=
SUM-225	NH\CdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfCZmkyKM7:TR?=	NW\0fllqPSCm	NGfsZ2ZFVVOR	NE\6fZpKSzVyPEGg{txO	NUixOJg5OjR6N{m3PVY>
EFM-192A	NX\LV3R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV2yZVkzOSEQvF2=	M{e1RlUh\A>?	NYnJfGdFTE2VTx?=	NUHTTllLUUN3MEyxJO69VQ>?	NYr2WI9wOjR6N{m3PVY>
JIMT-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjZcGc5OSEQvF2=	NWHXVXE6PSCm	Mn;NSG1UVw>?	M4LjXWlEPTB:MTFOwG0>	NEHSO5ozPDh5OUe5Oi=>
HCC1143	NFHlO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vwfFEh\|ryP	MVe1JIQ>	NHntU49FVVOR	MlS2TWM2ODxzIN88US=>	NVPseG1EOjR6N{m3PVY>
HCC2218	NYTh[o9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z2bFEh\|ryP	M2fH[\|Uh\A>?	NFnnTW5FVVOR	NXrSSYZDUUN3MEyxJO69VQ>?	M{jkSlI1QDd7N{m2
MDA-MB-468	NHHoWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO4NUDPxE1?	NWTaSnliPSCm	M3nmcWROW09?	NES4XoxKSzVyPEGg{txO	M1\ZWFI1QDd7N{m2
BT-20	NHnrUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTHZYpiOSEQvF2=	M{jRbFUh\A>?	M3KybWROW09?	MkK5TWM2ODxzIN88US=>	NGPaRnIzPDh5OUe5Oi=>
MDA-MB-435	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;aclEh\|ryP	NYPaTVNYPSCm	M2O1OGROW09?	NXXnRYh2UUN3MEyxJO69VQ>?	NVHJR\|hvOjR6N{m3PVY>
BT-549	NYXz[IE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH4S2pkOSEQvF2=	NHfkPGo2KGR?	MlPHSG1UVw>?	NYL0R\|BCUUN3MEyxJO69VQ>?	M2TCWlI1QDd7N{m2
HCC1806	NGTINXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DwcVEh\|ryP	NVXadZdtPSCm	MV\EUXNQ	NHnsNVNKSzVyPEGg{txO	NYHMU2lEOjR6N{m3PVY>
HCC1937	NFLXfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxJO69VQ>?	M37W[FUh\A>?	M{HQOmROW09?	MXLJR\|UxRDFizszN	NWPBWmFuOjR6N{m3PVY>
Hs578T	NVfDXXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHP2cWEyKM7:TR?=	NXfPfmZ3PSCm	NVjuWI11TE2VTx?=	Mnj4TWM2ODxzIN88US=>	M3vPUVI1QDd7N{m2
LN18	NFrVPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfhUGNSOjBizszN	M2LtcFczKGh?	M{jpUGROW09?	MlOzTWM2ODx3IN88US=>	M3vrUFI1PzRzMEe0
LN229	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELvbmgzOCEQvF2=	MojkO\|IhcA>?	MljaSG1UVw>?	MlTBTWM2ODx3IN88US=>	NHfMRWEzPDd2MUC3OC=>
LNZ308	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nXeVIxKM7:TR?=	NEPDN204OiCq	MlXqSG1UVw>?	MX7JR\|UxRDVizszN	NGLr[XAzPDd2MUC3OC=>
T98G	M1fScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7JclAzOCEQvF2=	MUm3NkBp	MmrCSG1UVw>?	MoLKTWM2ODx3IN88US=>	NV22N4JHOjR5NEGwO\|Q>
U87	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrid\|AzOCEQvF2=	MXu3NkBp	Ml;qSG1UVw>?	M1jtUmlEPTB:NTFOwG0>	M2LBZ\|I1PzRzMEe0
LN18	NVrzUpdbTnWwY4Tpc44hSXO\|YYm=	NE\6bWY2KM7:TR?=	NH73S5czPCCq	M2SwfGROW09?	Mn;lTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?	MVqyOFc1OTB5NB?=
LNZ308	NVjrcFNpTnWwY4Tpc44hSXO\|YYm=	NFP6V3Y2KM7:TR?=	NGKxb2YzPCCq	M1e4d2ROW09?	M3;lNWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	M{\s[lI1PzRzMEe0
Saos-2	MXHGeY5kfGmxbjDBd5NigQ>?	NEX2Z\|I2OCEQvF2=	M3nue\|Q5KGh?		MULJcohq[mm2czDj[YxtKGmwdnHzbY9v	MlXyNlQ4Ojd4NkC=
MG-63	NXr3UFV3TnWwY4Tpc44hSXO\|YYm=	M4n1XFUxKM7:TR?=	NWCzV2l5PDhiaB?=		M4jP[mlvcGmkaYTzJINmdGxiaX72ZZNqd25?	MYGyOFczPzZ4MB?=
SJSA-1	MXPGeY5kfGmxbjDBd5NigQ>?	MoO5OVAh\|ryP	NHn0WFI1QCCq		MXHJcohq[mm2czDj[YxtKGmwdnHzbY9v	M1XnO\|I1PzJ5Nk[w
Saos-2	M4f2VmZ2dmO2aX;uJGF{e2G7	NEH1cG42OCEQvF2=	NES0bWQ1QCCq		M3Hn[WlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	M4nmSFI1PzJ5Nk[w
MG-63	NXrUdYdiTnWwY4Tpc44hSXO\|YYm=	NG\1Xpg2OCEQvF2=	MYS0PEBp		M2LhZmlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	NUT1WlIxOjR5Mke2OlA>
SJSA-1	MoW0SpVv[3Srb36gRZN{[Xl?	NG\VVHY2OCEQvF2=	M1iySVQ5KGh?		MVHJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	MVGyOFczPzZ4MB?=
Saos-2	MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPTRVU2OCEQvF2=	M2HVcFQ5KGh?		M1nNWmlvcGmkaYTzJINmdGxidnnhZoltcXS7	M3zuelI1PzJ5Nk[w
MG-63	NIrH[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLDfYpOPTBizszN	NHXS[Zg1QCCq		MV7Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MWCyOFczPzZ4MB?=
SJSA-1	NX[4Z\|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PNTFUxKM7:TR?=	NY\yVI9RPDhiaB?=		M4DOUGlvcGmkaYTzJINmdGxidnnhZoltcXS7	MYKyOFczPzZ4MB?=
FaDu	MWHGeY5kfGmxbjDBd5NigQ>?	MUO1JO69VQ>?	MofqNlQhcA>?	MnewSG1UVw>?	NVj4cXVVWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	NVfRT3p[OjR4M{GxOFc>
EMT6	MYDGeY5kfGmxbjDBd5NigQ>?	MU[1JO69VQ>?	MV6yOEBp	MlPZSG1UVw>?	MU\S[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	MViyOFY{OTF2Nx?=
HCT116	MUfGeY5kfGmxbjDBd5NigQ>?	NFHzUmg2KM7:TR?=	MX[yOEBp	Mo\tSG1UVw>?	NUmyZlJOWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	MYiyOFY{OTF2Nx?=
U87	NY\ER4M3TnWwY4Tpc44hSXO\|YYm=	Ml7nOUDPxE1?	MUeyOEBp	NWnPdVZrTE2VTx?=	NVT0PHNVWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	NWrPXnd4OjR4M{GxOFc>
GBM	MYDBdI9xfG:\|aYOgRZN{[Xl?	NV3XeWFTOs7:TR?=	NFqyXYE1QGh?	MonOSG1UVw>?	MVXpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m\|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5	NHn1Um4zPDVyMES5Ni=>
BON	NXjJTnBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxMVXPxE1?	MVe3Nog>		NFS0TZFl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v	NGC2UJkzPDR2M{WyNy=>
BON	NFLaNo9CeG:ydH;zbZMhSXO\|YYm=	NIqxN\|YyNTYQvF2=	MmTTNlRp		MVLpcoNz\WG\|ZYOgZZBweHSxc3nz	MY[yOFQ1OzV{Mx?=
H1975	M3;adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;IN4dYOC5\|LUmuOu69VQ>?	NWjEN4xwPzKq	MXLEUXNQ	Ml3uTWM2OD1zLkO4Oe69VQ>?	MVyyOFM{Pzh2Nh?=
H1975	NU\Se\|hESXCxcITvd4l{KEG\|c3H5	NWnFXJJtOs7:TR?=	MX6yOIg>	M2LTN2ROW09?	MmPybY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk>	MXGyOFM{Pzh2Nh?=
T-ALL	M2Dy[WFxd3C2b4Ppd{BCe3OjeR?=	MknPZoV1f2WnbjCxMlQh[W6mIEWuN{BuVSCjdDCyOIgh[W6mIECuPUBidmRiNT61JI1OKGG2IES4bEBqdiCmaX\m[ZJmdnRiY3XscEBtcW6n	MknKNlQhd3JiNEjo	MXfEUXNQ	NIflfG1i\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=>	NVTZfHJXOjR\|MUC3N\|Y>
BCR-ABL	NX\KNm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfKdZpDOC5{NT2xNO69VQ>?	MlvWOIQ>		NGKxW2l{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w	NXH5[JdKOjR{NES2NVI>
LC-1/SQSF	MmLYSpVv[3Srb36gRZN{[Xl?	NUSyfm1QO87:TR?=	MUWyOIg>	MUPEUXNQ	NVnkUmxj\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt	MoPpNlM6QDByOUO=
Primary CLL cells	M1vNUWFxd3C2b4Ppd{BCe3OjeR?=	Mor1NU0yOM7:TR?=	MnHwOFhp		MlLPbY5lfWOnczDhdI9xfG:\|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=>	NIXoT\|UzOzh3MEiwOy=>
Primary CLL cells	M1W0TWtqdmG\|ZTDBd5NigQ>?	MUey{txO	NGPNZZU{OG2rbh?=		MWDk[YNz\WG\|ZXSgVGk{UyCjY4Tpeol1gQ>?	NWDBW4p[OjN6NUC4NFc>
Primary CLL cells	M3rwSWN6fG:2b4jpZ{BCe3OjeR?=	NY\SRmh[Os7:TR?=	M3v3[\|I1cA>?		MU\pcoR2[2W\|IHPlcIwh[3m2b4TvfIlkcXS7	MXuyN\|g2ODhyNx?=
human NSCLC cell lines	M4e2WGFxd3C2b4Ppd{BCe3OjeR?=	M36xU\|AvOTJ3LUVOwG0>	NHnwZoYzPGh?	M4C5WWROW09?	NFX6PVlKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=>	M3jIN\|I{PTZ{NEey
human HCC cell lines	M{HTNWNmdGxidnnhZoltcXS7IHHzd4F6	NFrMZowxNjByNT2x{txO	NVHTe2VnPDiq		NVjXbYlnUUN3ME2x{txO	NHPOXoEzOzR6OUm5PS=>
Huh7	NGPnS3FMcW6jc3WgRZN{[Xl?	MYCx{txO	MnHPOFhp		M2HOXpNq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=>	NUflfJJnOjN2OEm5PVk>
SK-HEP1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqxMVIx\|ryP	NHGwPWo4Omh?	MknoSG1UVw>?	MmX6TWM2OO,:nEJOwG0>	M1TWN\|I{PDd7MUO2
786-0	M1faRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjzNU0zOM7:TR?=	NVLWfVN5PzKq	M{HUbmROW09?	MWTJR\|Ux97zeMd88US=>	MlvmNlM1PzlzM{[=
JVM2	MlvjR5l1d3SxeHnjbZR6KGG\|c3H5	M4TQXVAvOi1{MN88US=>	MVi3Nog>	MmDFSG1UVw>?	NVj6WXZbUUN3ME2wMlnPxE1?	MVuyN\|I{QDZ\|OR?=
EHEB	NFjoSI5EgXSxdH;4bYNqfHliYYPzZZk>	NVOyPJdkOC5{LUKw{txO	M4fM[lczcA>?	M4j4VGROW09?	NWjNS29UUUN3ME2wMlfPxE1?	NFvHdoYzOzJ\|OE[zPS=>
MEC2	MkTIR5l1d3SxeHnjbZR6KGG\|c3H5	NFTGRpIxNjJvMkFOwG0>	NVnCeos{PzKq	NWHu[VdWTE2VTx?=	Mlu4TWM2OD1yLkhOwG0>	NIHBc4MzOzJ\|OE[zPS=>
primary B-CLL lymphocytes	MV3BdI9xfG:\|aYOgRZN{[Xl?	MmeyTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>?	NIrUPW8zPGh?	M4LVU2ROW09?	NUHBdJJnUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>?	M3jZ[VI{OjN6NkO5
primary B-CLL lymphocytes	NXn4NI15U2mwYYPlJGF{e2G7	Mkn3TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>?	MmPMNlRp		NV2xV2RocW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44>	NHL1R2MzOzJ\|OE[zPS=>
human NSCLC	M1P1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnmxNE42NTMQvF2=	NGLhXos4Omh?		NXO1T4J2UUN3ME2x{txO	NIfDfHMzOjd6MUO5Ny=>
human NSCLC	NVjJXY5lU2mwYYPlJGF{e2G7	Mk\yNe69VQ>?	M3ewTVI1cA>?		MYjpcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62	MY[yNlc5OTN7Mx?=
Y1 cell line	NUDVZoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPOXXFKOC5zzszNM\|HPxE1?	MmXNNlRp	NGW1VotFVVOR	NFT6RodqdmirYnn0d{A3OO,:hTDj[YxtKH[rYXLpcIl1gSCrbjDNfYMuW2O2cj30doFve2[nY4Tl[EBk\Wyucx?=	M{DEOlIzPjl{OUC0
PIK3CA-mutant MCF7	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjjXVZiT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd\|bl2=	NF\sZWE4Omh?		NVn1fHBWT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd\|bl2=	NEDy[ZkzOjZ3M{m2Oy=>
PIK3CA-mutant MCF7	NFHubZBMcW6jc3WgRZN{[Xl?	NX;3O5dJUUN3ME2xNVTDuTOwTR?=	M3HOXlczcA>?		NUXFe2JrUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=>	NVfiRZBmOjJ4NUO5Olc>
MCF7-myr-Akt	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nQS2dKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P	MV:3Nog>		Mlv1S2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1?	MXGyNlY2Ozl4Nx?=
colon cancer cell lines	NHTVSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjJbZMxNTFyzszN	MlKyO\|Jp	NGm3NJNFVVOR	NUTGbpBqUUN3ME2x{txO	MojmNlI2PDN6NUe=
gastric cancer cell lines	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnEUYgxNTFyzszN	MkDGO\|Jp	M4XnWWROW09?	NVfiSHhKUUN3ME2yMVXPxE1?	MVWyNlU1Ozh3Nx?=
HCT-116/HT-29/MKN-45	NEHhRWZCeG:ydH;zbZMhSXO\|YYm=	M{\hZ\|LPxE1?	NXjkRVI{PDiq		M{TCcpNpcW[2IHnuJGczKHCqYYPl	NXHBNo1mOjJ3NEO4OVc>
HT-29 and HCT-116	M1\IcWNie3Cjc3WgZZN{[Xl?	NVj6c2FrPc7:TR?=	NX7DU4FMOjSq		MYjpcoR2[2W\|IHPhd5Bie2ViYXP0bZZqfHl?	NUn0[IxiOjJ3NEO4OVc>
MM cell lines	NVP6d5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M125[VEx\|ryP	M3f3XVI1cA>?	M{e2R2ROW09?	NUL0R41oUUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn	MkmyNlIzODd2OEW=
ARP-1	MlPVRZBweHSxc3nzJGF{e2G7	NF;xV20yOM7:TR?=	NYr2fmRIOjSq	MYLEUXNQ	M1vaSolv\HWlZYOgUW0h[2WubDDhdI9xfG:\|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36=	MYeyNlIxPzR6NR?=
SNU-601	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3LQSFczcA>?	NELWdIpFVVOR	MkjzTWM2OD1yLkixOuKyOC5yNkROwG0>	M3P5[FIzOTV7OEG0
SNU-1	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFHFdJI4Omh?	M{PyWmROW09?	NVn5fHBqUUN3ME2xMlA5OsLzMD6wNljPxE1?	NXThVIZUOjJzNUm4NVQ>
SNU-668	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFLtfFE4Omh?	M2nES2ROW09?	NUDr[Hh[UUN3ME2xMlU4QcLzMD6wO\|TPxE1?	NHnoZYkzOjF3OUixOC=>
AGS	NYSxRVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW3Nog>	MUPEUXNQ	NX;TOYw5UUN3ME2xMlcyPMLzMD6xNVfPxE1?	NEnUTm4zOjF3OUixOC=>
SNU-216	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1W5O\|czcA>?	Ml7nSG1UVw>?	NXjDUG05UUN3ME2yMlY6OsLzMD6wPFLPxE1?	M3f3eVIzOTV7OEG0
SNU-5	NHTkZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV63Nog>	MXLEUXNQ	NXvDPHl[UUN3ME2xMlM2OcLzMD6wPVHPxE1?	NWS4OGp6OjJzNUm4NVQ>
SNU-638	NE\SUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV:3Nog>	NV31elVJTE2VTx?=	M4D6N2lEPTB;Mj6yPFLDuTBwMEWz{txO	NXTXdI9OOjJzNUm4NVQ>
SNU-16	NYSzSplkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDNO\|Jp	MVjEUXNQ	NITsc\|VKSzVyPUGuOVc{yrFyLkCwNe69VQ>?	Ml;QNlIyPTl6MUS=
SNU-484	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmjlO\|Jp	NWXVZ2xuTE2VTx?=	NUfLd3d[UUN3ME2xMlczQMLzMD6wOFXPxE1?	NHLpcIYzOjF3OUixOC=>
SNU-620	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fkR\|czcA>?	M1uzW2ROW09?	Ml\ZTWM2OD1{LkmzPeKyOC5yMEJOwG0>	NHOxbWwzOjF3OUixOC=>
SNU-719	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoLlO\|Jp	M{LiRmROW09?	MknpTWM2OD1\|LkCzO:KyOC5yM{NOwG0>	M4CzU\|IzOTV7OEG0
glioma cell lines	NYO3ZlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVPHSohsPzKq		NXW3PXhLUUN3ME2xMVLPxE1?	NWHmc4xmOjJyNkWwPFA>
U87	NGj0WY5CeG:ydH;zbZMhSXO\|YYm=	MoHxNu69VQ>?	NFT3bog4Omh?		NVPzdpU3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM>	NWHzbmN4OjJyNkWwPFA>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	- 合并 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	- 合并 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Formulation: 15% Captisol Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- 合并

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120, NVP-BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2
NCT01953445	Withdrawn	Drug: paclitaxel\|Drug: BKM120	Breast Neoplasms	Washington University School of Medicine	August 2014	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

Buparlisib (BKM120, NVP-BKM120)

客户使用Selleck该产品发表文献135篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120, NVP-BKM120) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品